Hostname: page-component-f554764f5-8cg97 Total loading time: 0 Render date: 2025-04-12T11:16:02.915Z Has data issue: false hasContentIssue false
  • English
  • Français

Antipsychotic drugs: is more worse? a meta-analysis of the published randomized control trials

Published online by Cambridge University Press:  09 July 2009

P. Bollini ,
S. Pampallona ,
M. J. Orza ,
M. E. Adams  and
T. C. Chalmers
P. Bollini*
Affiliation:
Technology Assessment Group, Harvard School of Public Health, Boston, MA., USA
S. Pampallona
Affiliation:
Technology Assessment Group, Harvard School of Public Health, Boston, MA., USA
M. J. Orza
Affiliation:
Technology Assessment Group, Harvard School of Public Health, Boston, MA., USA
M. E. Adams
Affiliation:
Technology Assessment Group, Harvard School of Public Health, Boston, MA., USA
T. C. Chalmers
Affiliation:
Technology Assessment Group, Harvard School of Public Health, Boston, MA., USA
*
1 Address for correspondence: Dr Paola Bollini, I.O.M., 17 Route des Morillons, 1211 Geneva, Switzerland
Get access Rights & Permissions [Opens in a new window]

Synopsis

Effectiveness and side-effects of high- versus low-dose neuroleptic treatment of chronic psychosis have been assessed through a meta-analysis of 22 published randomized control trials comparing different neuroleptic doses. No incremental clinical improvement was found at doses above 375 mg equivalent of chlorpromazine, while a significant increase in adverse reactions was observed.

Type
Original Articles
Information
Psychological Medicine , Volume 24 , Issue 2 , May 1994 , pp. 307 - 316
Copyright
Copyright © Cambridge University Press 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Anderson, W. H. & Kuehnle, J. C. (1976). Dosage of antipsychotic drugs. New England Journal of Medicine 294, 670.Google ScholarPubMed
Aubrée, J. C. (1979). Le problème des posologies des neuroleptiques et leurs variations géographiques. Mémoire de Psychiatrie, Université René Descartes (Paris V).Google Scholar
Aubrée, J. C. & Lader, M. H. (1980). High and very high dosage antipsychotics: a critical review. Journal of Clinical Psychiatry 41, 341–350.Google ScholarPubMed
Ayd, F. J. Jr. (1977). Guidelines for using short-acting intramuscular Neuroleptics for rapid neuroleptisation. International Drug Therapy Newsletter 12, 5–12.Google Scholar
Baldessarini, R. J. (1985). Chemotherapy in Psychiatry. Principles and Practice. Harvard University Press: Cambridge, MA.Google Scholar
Baldessarini, R. J. & Davis, J. M. (1980). What is the best maintenance dose of Neuroleptics in schizophrenia? Psychiatry Research 3, 115–122.CrossRefGoogle ScholarPubMed
Baldessarini, R. J., Gelenberg, A. J. & Lipinski, J. F. (1976). Grams of antipsychotics? New England Journal of Medicine 294, 113–114.Google ScholarPubMed
Baldessarini, R. J., Cole, J. O., Davis, J. M., Gardos, G., Simpson, G. & Tarsy, D. (1980). Tardive Dyskinesia. Task Force Report no. 18. American Psychiatric Association: Washington DC.Google Scholar
Baldessarini, R. J., Katz, B. & Cotton, P. (1984). Dissimilar dosing with high-potency and low-potency neuroleptics. American Journal of Psychiatry 141, 748–752.Google ScholarPubMed
Baldessarini, R. J., Cohen, B. M. & Teicher, M. (1988). Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry 45, 79–91.CrossRefGoogle ScholarPubMed
Begg, C. G. & Berlin, J. A. (1989). Publication bias and dissemination of clinical research. Journal of National Cancer Institute 81, 107–115.CrossRefGoogle ScholarPubMed
Bjorndal, N., Bjerre, M., Gerlach, J., Kristjansen, P., Magelund, G., Oestrich, I. H. & Waehrens, J. (1980). High dosage haloperidol therapy in chronic schizophrenic patients: a double blind study of clinical response, side effects, serum haloperidol, and serum prolactin. Psychopharmacology 67, 17–23.CrossRefGoogle ScholarPubMed
Bollini, P., Andreani, A., Colombo, F., Bellantuono, C.Beretta, P., Arduini, A., Galli, T. & Tognoni, G. (1984). High-dose neuroleptics: uncontrolled clinical practice confirms controlled clinical trials. British Journal of Psychiatry 144, 25–27.CrossRefGoogle ScholarPubMed
Branchey, M. H., Branchey, L. B. & Richardson, M. A. (1981). Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients. American Journal of Psychiatry 138, 608–612.Google ScholarPubMed
Brotman, R. K., Muzekari, L. H. & Shanken, P.M. (1969). Butaperazine in chronic schizophrenic patients: a double blind study. Current Therapeutic Research 11, 5–8.Google Scholar
Caffey, E. M., Diamond, L. S., Frank, T. V., Grasberger, J. C., Herman, L., Klett, C. J. & Rothstein, C. (1964). Discontinuation or reduction of chemotherapy in chronic schizophrenics. Journal of Chronic Diseases 17, 347–358.CrossRefGoogle ScholarPubMed
Carpenter, W. T., Heinrichs, D. W. & Hanlon, T. E. (1987). A comparative trial of pharmacologic strategies in schizophrenia. American Journal of Psychiatry 144, 1466–1470.Google ScholarPubMed
Chien, C. P. (1975). Drugs and rehabilitation in schizophrenia. In Drugs in Combination with Other Therapies (ed. Greenblatt, M.), pp. 13–34. Grune and Stratton: New York.Google Scholar
Chouinard, G. & Annable, L. (1976). Alpha-methyldopa-chlorpromazine combination in schizophrenic patients. Neuropsychobiology 2, 118–126.CrossRefGoogle ScholarPubMed
Clark, M. L., Ramsey, H. R., Ragland, R. E., Rahhal, D. K., Serafetinides, E. A. & Costiloe, J. P. (1970). Chlorpromazine in chronic schizophrenia: behavioral dose–response relationships. Psychopharmacologia (Berl.) 18, 260–270.CrossRefGoogle ScholarPubMed
Clark, M. L., Paredes, A., Costiloe, J. P., Fulkerson, F. G. & Wood, F. (1977). Evaluation of two dose levels of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System 38, 7–10.Google ScholarPubMed
Cookson, I. B. (1987). The effects of a 50% reduction of Ciz(z)-Flupenthixol Decanoate in chronic schizophrenic patients maintained on a high dose regime. International Clinical Psychopharmacology 2, 141–149.CrossRefGoogle Scholar
De Buck, R. P. (1972). Relative safety and efficacy of high and low dose administration of fluphenazine HC1 to psychotic patients. In Proceedings of the Eighth International Congress of Neuropsychopharmacology, Excerpta Medica, International Congress Series No. 148, pp. 265–272. Princeton, NJ.Google Scholar
Delay, J. & Deniker, P. (1952). Trente-huit cases de psychoses traitées par la cure prolongée et continue de 4560RP. Le Congrès des A1. et Neurol. de Langue Française. In Compte Rendue du Congrès, Masson et Cie: Paris.Google Scholar
Deneker, S. J., Johansson, R., Lundin, L. & Malm, U. (1978). High doses of fluphenazine enanthate in schizophrenia: a controlled study. Acta Psychiatrica Scandinavica 57, 405–414.CrossRefGoogle Scholar
Easterbrook, P. J., Berlin, J. A., Gapalan, R. & Matthews, D. R. (1991). Publication bias in clinical research. Lancet 337, 867–872.CrossRefGoogle ScholarPubMed
Eriksen, S. E., Hurt, S. W. & Davis, J. M. (1976). Dosage of antipsychotic drugs. New England Journal of Medicine, 294, 1296–1297.Google Scholar
Faleni, R. A. (1970). The use of high doses of fluphenazine in the treatment of psychotic patients. Psychosomatics 11, 496–499.CrossRefGoogle ScholarPubMed
Gardos, G. & Cole, J. O. (1973). The importance of dosage in antipsychotic drug administration. A review of dose-response studies. Psychopharmacologia (Berlin) 29, 221–230.CrossRefGoogle ScholarPubMed
Gardos, G., Hecht Orzack, M., Finn, G. & Cole, J. (1974). High and low dose thiothixene treatment in chronic schizophrenia. Diseases of the Nervous System 35, 53–58.Google ScholarPubMed
Glass, G. V. (1976). Primary, secondary, and meta-analysis of research. Educational Research 5, 3–8.CrossRefGoogle Scholar
Goldberg, S. C. (1987). Persistent flaws in the design and analysis of psychopharmacology research. In Psychopharmacology: the Third Generation of Progress (ed. Meltzer, H. Y.), pp. 1005–1012. Raven Press: New York.Google Scholar
Goldstein, M. J., Rodnick, E. H., Evans, J. R., May, P. R. A. & Steinberg, M. R. (1978). Drug and family therapy in the aftercare of acute schizophrenics. Archives of General Psychiatry 35, 1169–1177.CrossRefGoogle ScholarPubMed
Hogarty, G. E., McEvoy, J. P., Munetz, M., DiBarry, A. L., Bartone, P., Cather, R., Cooley, S. J., Ulrich, R. F., Carter, M. & Madonia, M. J. (1988). Dose of Fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. Archives of General Psychiatry 45, 797–805.CrossRefGoogle ScholarPubMed
Holloway, F. (1988). Prescribing for the long-term mentally ill. A study of treatment practices. British Journal of Psychiatry 152, 511–515.CrossRefGoogle ScholarPubMed
Huang, C. C., Gerhardstein, R. P., Kim, D. Y. & Hollister, L. (1987). Treatment-resistant schizoprenia: controlled study of moderate-and high-dose thiothixene. International Clinical Psychopharmacology 2, 69–75.CrossRefGoogle Scholar
Johnson, D. A. W., Ludlow, J. M., Street, K. & Taylor, R. D. W. (1987). Double blind comparison of half-dose and standard-dose Flupenthixol Decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. British Journal of Psychiatry 151, 634–638.CrossRefGoogle ScholarPubMed
Kane, J. M., Rifkin, A., Woerner, M., Reardon, G., Sarantakos, S., Schiebel, D. & Ramos-Lorenzi, J. (1983). Low-dose neuroleptic treatment of outpatient schizophrenics. Archives of General Psychiatry 40, 893–896.CrossRefGoogle ScholarPubMed
Kane, J. M., Woerner, M. & Sarantakos, S. (1986). Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens. Journal of Clinical Psychiatry 47 (5, Suppl), 30–33.Google ScholarPubMed
Karon, B. P. (1989). Psychotherapy versus medication for schizophrenia: empirical comparisons. In The Limits of Biological Treatments for Psychological Distress. Comparisons with Psychotherapy and Placebo (ed. Fisher, S. and Greenberg, R. P.), pp. 105–150. Lawrence Erlbaum Associates Publishers: Hillsdale, NJ.Google Scholar
Louis, T., Fineberg, H. V. & Mosteller, F. (1985). Findings for public health from meta-analyses. Annals Review of Public Health 6, 1–20.CrossRefGoogle ScholarPubMed
McClelland, H. A., Farquharson, R. G., Leyburn, P., Furness, J. A. & Schiff, A. A. (1976). Very high dose fluphenazine decanoate. A controlled trial in chronic schizophrenia. Archives of General Psychiatry 33, 1435–1439.CrossRefGoogle ScholarPubMed
McCreadie, R. G., Flanagan, W. L., McKnight, J. & Jorgensen, A. (1979). High dose flupenthixol decanoate in chronic schizophrenia. British Journal of Psychiatry 135, 175–179.CrossRefGoogle ScholarPubMed
Magno Zito, J., Craig, T., Wanderling, J. & Siegel, C. (1987). Pharmaco-epidemiology in 136 hospitalized schizophrenic patients. American Journal of Psychiatry 144, 778–782.Google Scholar
Marder, S. R., Van Putten, T., Mintz, J., Lebell, M., McKenzie, J. & May, P. R. A. (1987). Low- and conventional-dose maintenance therapy with Fluphenazine Decanoate. Archives of General Psychiatry 44, 518–521.CrossRefGoogle ScholarPubMed
Morgenstern, H., Glazer, W. M., Niedzwiecki, D. & Nourjah, P. (1987). The impact of neuroleptic medication on tardive dyskinesia: a meta-analysis of published studies. American Journal of Public Health 77, 717–724.CrossRefGoogle ScholarPubMed
Nishikawa, T., Tsuda, A., Tanaka, M., Hoaki, I., Koga, I. & Uchida, Y. (1984). Prophylactic effect of neuroleptics in symptom-free schizophrenics: a comparative dose-response study of haloperidol and propericiazine. Psychopharmacology 82, 153–156.CrossRefGoogle ScholarPubMed
Nishikawa, T., Tsuda, A., Tanaka, M., Koga, I. & Uchida, Y. (1985). Prophylactic effects of neuroleptics in symptom-free schizophrenics: roles of dopaminergic and noradrenergic blockers. Biological Psychiatry 20, 1161–1166.CrossRefGoogle ScholarPubMed
Oldham, A. J. & Bott, M. (1971). The management of excitation in a general hospital psychiatric ward by high dosage haloperidol. Acta Psychiatrica Scandinavica 47, 369–376.CrossRefGoogle Scholar
Overall, J. E. & Gorham, D. R. (1962). The brief psychiatric rating scale. Psychological Reports 10, 799–812.CrossRefGoogle Scholar
Prien, R. F. & Cole, J. O. (1968). High dose chlorpromazine therapy in chronic schizophrenia. Archives of General Psychiatry 18, 482–495.CrossRefGoogle Scholar
Prien, R. F., Levine, J. & Cole, J. O. (1969). High dose trifluoperazine therapy in chronic schizophrenia. American Journal of Psychiatry 126, 305–313.CrossRefGoogle ScholarPubMed
Quitkin, F., Rifkin, A. & Klein, D. F. (1975). Very high dosage vs standard dosage fluphenazine in schizophrenia. A double-blind study of nonchronic treatment-refractory patients. Archives of General Psychiatry 32, 1276–1281.CrossRefGoogle ScholarPubMed
Reardon, G. T., Rifkin, A., Schwartz, A., Myerson, A. & Siris, S. (1989). Changing patterns of neuroleptic dosage over a decade. American Journal of Psychiatry 146, 726–728.Google ScholarPubMed
Reitman, D., Sacks, H. S. & Chalmers, T. C. (1987). Technical quality assessment of randomized control trials (RCTs). Controlled Clinical Trials 8, 232.Google Scholar
Sacks, H. S., Berrier, J., Reitman, D., Ancona-Berk, V. A. & Chalmers, T. C. (1987). Meta-analysis of randomized controlled trials. New England Journal of Medicine 316, 450–455.CrossRefGoogle Scholar
Sangiovanni, F., Taylor, M. A., Abrams, R. & Gaztanaga, P. (1973). Rapid control of psychotic excitement states with intramuscular haloperidol. American Journal of Psychiatry 130, 1155–1156.CrossRefGoogle ScholarPubMed
Schneider, L. S., Pollock, V. E. & Lyness, S. A. (1990). A metaanalysis of controlled trials of neuroleptic treatment in dementia. Journal of the American Geriatric Society 38, 553–563.CrossRefGoogle ScholarPubMed
Simpson, G. M., Amin, M., Kunz-Bartholini, E., Watts, T. P. S. & Laska, E. (1968). Problems in the evaluation of the optimal dose of a phenothiazine (butaperazine). Diseases of the Nervous System 29, 478–484.Google ScholarPubMed
Venulet, J., Blattner, R., von Bulow, J. & Berneker, G. C. (1982). How good are articles on adverse drug reactions? British Medical Journal 284, 1792–1794.CrossRefGoogle ScholarPubMed
Wiles, D., Franklin, M., Deneker, S. J., Johansson, R., Lundin, L. & Malm, U. (1980). Plasma Fluphenazine and prolactin levels in schizophrenic patients during treatment with low and high doses of fluphenazine enanthate. Psychopharmacology 71, 131–136.CrossRefGoogle ScholarPubMed
Williams, J. R., Solecki, R. T. & Putkammer, S. (1969). Effects of single, combined and non-drug treatments on chronic mental patients. (A preliminary study.) Diseases of the Nervous System 30, 696–701.Google ScholarPubMed